Arovella Therapeutics Limited (ALAO) Quote

I seen both of those PR on Yahoo Finance and on Market Watch as well as on my Etrade account... where are you not seeing it. Here is the link to MarketWatch
https://www.marketwatch.com/investing/stock/affu

$MULN Bankruptcy coming

trial was terminated in March 2022, just months before DCVax-L’s glioblastoma data was published in Nature Communications.


When did Merck started West Point construction?

Perhaps related....All waiting on approval of DCVax-L

I think 200% is a big wish. If it was up 100% already then maybe. Got the volume but not the pps

Ixhl .22 top line phase 2 data anyday .. https://schrts.co/DAbqsvbD

The narrative is in the filings which is what I post. They need some volume for the second tranche of IBH Capital conversions that have yet to land at the DTC from what I see. Those shares converted at $0.00068 so they need to pump the he77 out of this once again. Those conversions are teh bulk of t

Looks like a complicated way to make the offering look good but guarantee no losses?
Not like the usual toxic notes with their discounted conversion ratios.

Fired doctor grovels after her foul post suggesting flood victims were Trump supporters who got ‘what they voted for’ sparked outrage
By Patrick Reilly Published July 10, 2025, 7:33 a.m. ET
(Too little. Too late... I hope this despicable, stupid c-word pays for this for the rest of he

$MULN Mullen Automotive (MULN) is facing a number of securities fraud lawsuits related to alleged misleading statements and omissions, including those concerning reverse stock splits. Investors claim the company misrepresented its intentions and financial standing, leading to stock price drops. Mull

Homework: Oxford?Ionics is a UK-based quantum computing startup (spun out of Oxford University in 2019), specializing in trapped-ion quantum processors fabricated on standard semiconductor chips, achieving world-leading gate fidelities—often cited as “one error in 6.7?million operations” ?.

"On Monday, July 14, 2025, the Federal Reserve will implement the ISO 20022 message format for Fedwire Funds messages. This will be a single-day implementation with the sunsetting of the existing proprietary FAIM format. As previously noted, members will be required to use the instructions below for

PreMarket is Strong. Must be something behind our bush too.

LAST PRICE
2.4100 (yesterday)

Premarket as high as $2.75
Bid / Lots
2.7100/ 3
Ask / Lots
2.7200/ 3,760

Open / Previous Close
--- / 2.4100
Day Ran

Thanks Talon for the complimentary post. Yes, I’ve been in the healthcare field since college. My father & two uncles were pharmacists & one uncle a country doctor. I obtained a degree in biology & retired from a medical diagnostics company several years ago. My hoppy is “betting on biotechs” 

Up 20% premarket. Looks like people like that MP news of $1 billion in Department of defense funding. All boats rising?

It's likely that they will wait until Monday to send an update so it is at the beginning of the week instead of Friday, which may cause the message to lose momentum by best week. 

GERN- Goldman Sachs downgrade

has zero meaning IMO, as the company has EU approval now, and phase 3 studies still ongoing for expanded use of Rytelo for Myelofibrosis in 2026 or 2027, which no one has a drug for. Bristol Myers has killed GERN sales for Rytelo for the use in low r

>>>.... so naturally you attempt to throw your own biased opinion of the effectiveness of the product.

$ADHC https://x.com/ADHCMANAGEMENT/status/1942999760278847926?t=Ju6q_FIfC74LfwMQ6Y83Xw&s=19

I think some point of the day or morning they’ll get interested again☝️🥳☝️

Look up the poverty rate in sweet home Chicago, just for fun...

Your GDP comes from the multinationals based there, 100s of billions you brag about, right ?

You'd think with all that wealth right there in one spot, it would be a spotless shining city that's the envy o

GM $treet!!

$VSEE is revolutionizing stroke rehab with NIH-backed tech!

• Phase 3 trials opens doors for Medicare and private payer reimbursement and opportunities in the $328M global stroke rehab market
•think $VVOS type news coming
https://youtu.be/f_ncSOpvaMo

$VSEE is revolutionizing stroke rehab with NIH-backed tech!

• Phase 3 trials opens doors for Medicare and private payer reimbursement and opportunities in the $328M global stroke rehab market
•think $VVOS type news coming
https://youtu.be/f_ncSOpvaMo

$ADHC https://x.com/ADHCMANAGEMENT/status/1942999760278847926?t=Ju6q_FIfC74LfwMQ6Y83Xw&s=19